Form 4: Cidara Therapeutics Director Joshua Resnick Reports Stock Option Grant

Cidara Therapeutics, Inc. Director Joshua Resnick has reported the acquisition of 5,079 stock options with an exercise price of $21.31, granted on June 18, 2025, as part of his annual director compensation.

Summary

• Joshua Resnick, a Director of Cidara Therapeutics, Inc. (CDTX), was granted 5,079 stock options.
• The options have an exercise price of $21.31 per share.
• The grant date for these options was June 18, 2025.
• The options are part of an annual director stock option grant, which is pro-rated based on the number of days served on the board prior to the grant date.
• The shares subject to the option will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.
• The options are set to expire on June 17, 2035.
• Mr. Resnick holds the option for the benefit of RA Capital Healthcare Fund, L.P., and disclaims beneficial ownership, as he is obligated to turn over any net cash or stock received upon exercise to RA Capital Management, L.P., to offset advisory fees.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider transaction (stock option grant) and does not contain information that would significantly alter the company's outlook or financial position, thus maintaining a neutral sentiment.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the value of the options increases with the company's stock price, incentivizing long-term growth.

Negatives

• The pro-rated nature of the grant indicates that the full annual grant of 11,100 shares was not received, which is a factual detail rather than an inherent negative.

Risks

• The value of the stock options is contingent on the future market price of Cidara Therapeutics' common stock, meaning they could become worthless if the stock price falls below the exercise price.

Future Outlook

The stock options are set to vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders, and will expire on June 17, 2035, indicating a long-term incentive structure for the director.

Management Comments

• "Annual director stock option grant of 11,100 shares is pro-rated based on the number of days served on the Issuer's board of directors prior to the grant date divided by 365 days."
• "The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders."
• "Under the Reporting Person's arrangement with RA Capital Management, L.P. (the 'Adviser'), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the 'Fund'). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common in the biotechnology and pharmaceutical industries, where director compensation frequently includes equity grants to align leadership incentives with long-term company performance and shareholder value.

Related Party Transactions

• The reporting person, Joshua Resnick, holds the stock option for the benefit of RA Capital Healthcare Fund, L.P., and is obligated to turn over any net cash or stock received upon exercise to RA Capital Management, L.P., to offset advisory fees. This arrangement constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value. Future exercise of options could lead to minor dilution.
• Management/Directors: Provides equity-based compensation and a long-term incentive for the director, linking their personal financial success to the company's long-term growth.

Next Steps

• Vesting of the granted stock options on or before June 18, 2026, or the day prior to the 2026 annual meeting.
• Potential exercise of the stock options by the director before their expiration on June 17, 2035.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Form 4, SEC filing, insider transaction, stock option, director compensation, Joshua Resnick, RA Capital, beneficial ownership